199,953 Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 199,953 shares of the company's stock, valued at approximately $3,955,000. Raymond James Financial Inc. owned about 0.28% of Kiniksa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Cerity Partners LLC purchased a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $834,000. Algert Global LLC boosted its holdings in shares of Kiniksa Pharmaceuticals by 390.0% in the third quarter. Algert Global LLC now owns 91,159 shares of the company's stock valued at $2,278,000 after acquiring an additional 72,556 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $354,000. FMR LLC raised its position in Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company's stock valued at $17,413,000 after purchasing an additional 694,928 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Kiniksa Pharmaceuticals by 121.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 192,926 shares of the company's stock worth $4,821,000 after purchasing an additional 105,924 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Remove Ads

Kiniksa Pharmaceuticals Stock Performance

NASDAQ KNSA traded down $0.27 during mid-day trading on Friday, reaching $23.09. 1,544,612 shares of the stock were exchanged, compared to its average volume of 445,442. The stock has a market capitalization of $1.68 billion, a PE ratio of -164.92 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The business's fifty day simple moving average is $20.77 and its 200 day simple moving average is $21.98.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $122.50 million for the quarter, compared to analysts' expectations of $123.42 million. During the same quarter in the previous year, the business posted $0.35 earnings per share. The business's quarterly revenue was up 46.9% compared to the same quarter last year. On average, analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the transaction, the chief operating officer now owns 88,975 shares of the company's stock, valued at approximately $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the completion of the transaction, the chief accounting officer now owns 26,528 shares of the company's stock, valued at approximately $595,553.60. The trade was a 25.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,766 shares of company stock valued at $2,011,735 in the last quarter. Company insiders own 54.57% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on KNSA. Wedbush restated an "outperform" rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $37.17.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.